Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008

Abstract

Introduction

2008 came to a close amid political transition in the world' s largest pharmaceutical market and economic upheaval in all of the world' s markets. Our review of key events that occurred in the fourth quarter and prominent trends at play in that time frame refl ects that backdrop and fi nds that companies in the biopharma industry have an opportunity to move outside of traditional models to tap new opportunities - and some are making big strides in doing so.

Get the Answers You Need to Shape Your Strategy

• There' s a new administration in Washington. What are the prospects for expanded care? What are the targets of cost-containment? How do administration policies present opportunity for the biopharma industry?
• Healthcare is generally regarded as a stable industry in a down economy, but biopharma is feeling the effects of the global recession. How is access to healthcare changing? How is access to funding changing? How are biopharma companies affected, and how are they adjusting their general business and dealmaking strategies?
• Spectrum has advised the industry to adapt to inevitable changes in the industry. What are the promising strategies and new directions for biopharma companies? How can companies turn challenges into opportunities?

Scope

• Events: political change in the United States and United Kingdom, effects of the economy on the industry' s fortunes, new moves on the lifestyle drugs landscape, new competitive considerations in the emerging market of China.
• Dealmaking: deal type, deal value, deal focus, most active companies, therapeutic areas.
• Generics: related deals, biosimilars, Big Pharma participation, early competition for clopidogrel, opening of the Japanese market.
• Strategy: the varied affect of the economy on biotechs versus Big Pharma; new imperatives in the response to the economy; new scrutiny of Big Pharma responses to generic competition.
• Expert commentaries: generics industry perspectives, strategy perspectives, U.K. policy news perspective, Japanese biosimilar industry news perspective, Chinese intellectual property news perspective, Lilly' s fourth-quarter dealmaking strategy perspective.

Mentioned in This Spectrum Report

• Companies
  • Abbott
  • Acino
  • Actavis
  • Actavis Totowa
  • AFFiRiS
  • Affymetrix
  • Allergan
  • Archemix
  • Aska
  • Aspen
  • AstraZeneca
  • AtheroGenics
  • Bayer
  • Biogen Idec
  • BioVest
  • Bristol-Myers Squibb
  • Bristol-Myers Squibb Pakistan
  • Caraco
  • Cel-Sci
  • Cephalon
  • Chad
  • Chugai
  • CT Arzneimittel
  • CureMark
  • Cyntellect
  • Daiichi Sankyo
  • Deciphera Pharmaceuticals
  • Dynavax Technologies
  • Eisai
  • Ethicon
  • Exelixis
  • Genelabs Technologies
  • Genentech
  • Genzyme
  • Geron
  • GlaxoSmithKline
  • GlycArt Biotechnology
  • HealthMedia
  • Hexal
  • ImClone
  • Janssen Pharmaceutica
  • Johnson & Johnson
  • Jointown Group
  • Lev
  • LGE Performance Systems
  • Eli Lilly
  • Kissei Seiyaku
  • Kowa
  • Lpath Therapeutics
  • Lupin
  • MAP Pharmaceuticals
  • MDRNA
  • MedImmune
  • Medivation
  • Memory Pharmaceuticals
  • Mentor
  • Merck
  • Merck BioVentures
  • Merck Generics
  • Merck KGaA
  • Merck Serono
  • MicroIslet
  • Mylan
  • Neuropharm
  • Nippon Chemical Research
  • Novartis
  • Novocell
  • OMRIX Biopharmaceuticals
  • OncoGenex
  • Orchestra Therapeutics
  • Osiris Therapeutics
  • Otsuka
  • Pfi zer
  • PGx Health
  • Ranbaxy
  • Ratiopharm
  • ReNeuron
  • Roche
  • Sandoz
  • Sanofi -Aventis
  • Schwarz Pharma
  • Schweizerhall
  • Shanghai Pharma
  • Sinopharm
  • Spectrum Pharmaceuticals
  • Strides-Arcolab
  • Sun Pharmaceutical Industries
  • Synta Pharmaceuticals
  • Teva
  • Thiakis
  • Viropharma
  • WuXi PharmaTech
  • Wyeth
  • Zentiva
  • Zydus-Cadila